You will be provided with a reference and some statements. Please determine whether each statement is 'supported', 'unsupported', or 'unknown' with respect to the reference. Please note:
First, assess whether the reference contains any valid content. If the reference contains no valid information, such as a 'page not found' message, then all statements should be considered 'unknown'.
If the reference is valid, for a given statement: if the facts or data it contains can be found entirely or partially within the reference, it is considered 'supported' (data accepts rounding); if all facts and data in the statement cannot be found in the reference, it is considered 'unsupported'.

You should return the result in a JSON list format, where each item in the list contains the statement's index and the judgment result, for example:
[
    {
        "idx": 1,
        "result": "supported"
    },
    {
        "idx": 2,
        "result": "unsupported"
    }
]

Below are the reference and statements:
<reference>
1. Circulation. 2020 Mar 3;141(9):728-739. doi:
10.1161/CIRCULATIONAHA.119.044195.  Epub 2019 Nov 11.

Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on 
Hemodialysis: Results of a Randomized Phase 2b Study.

Raggi P(1), Bellasi A(2), Bushinsky D(3), Bover J(4), Rodriguez M(5), Ketteler 
M(6), Sinha S(7), Salcedo C(8), Gillotti K(9), Padgett C(9), Garg R(9), Gold 
A(9)(10), Perelló J(8)(11), Chertow GM(10).

Author information:
(1)Department of Medicine, Mazankowski Alberta Heart Institute and University of 
Alberta, Edmonton, Canada (P.R.).
(2)Research, Innovation and Brand Reputation Unit, ASST Papa Giovanni XXIII, 
Bergamo, Italy (A.B.).
(3)Department of Medicine, University of Rochester Medical Center, NY (D.B.).
(4)Department of Nephrology, Fundació Puigvert and Universitat Autònoma, IIB 
Sant Pau, REDinREN, Barcelona, Spain (J.B.).
(5)Nephrology Unit, Hospital Universitario Reina Sofia, IMIBIC, REDinREN, 
Córdoba, Spain (M.R.).
(6)Department of General Internal Medicine and Nephrology, 
Robert-Bosch-Krankenhaus, Stuttgart, Germany (M.K.).
(7)Department of Renal Medicine, Salford Royal NHS Foundation Trust, UK (S.S.).
(8)Research and Development, Sanifit Therapeutics, Palma, Spain (C.S., J.P.).
(9)Research and Development, Sanifit Therapeutics, San Diego, CA (K.G., C.P. 
R.G., A.G.).
(10)Department of Medicine, Stanford University, Palo Alto, CA (A.G., G.M.C.).
(11)University of the Balearic Islands, Palma, Spain (J.P.).

Comment in
    Circulation. 2020 Mar 3;141(9):740-742. doi: 
10.1161/CIRCULATIONAHA.119.044801.

BACKGROUND: The high cardiovascular morbidity and mortality in patients with 
end-stage kidney disease could be partially caused by extensive cardiovascular 
calcification. SNF472, intravenous myo-inositol hexaphosphate, selectively 
inhibits the formation and growth of hydroxyapatite.
METHODS: This double-blind, placebo-controlled phase 2b trial compared 
progression of coronary artery calcium volume score and other measurements of 
cardiovascular calcification by computed tomography scan during 52 weeks of 
treatment with SNF472 or placebo, in addition to standard therapy, in adult 
patients with end-stage kidney disease receiving hemodialysis. Patients were 
randomized 1:1:1 to SNF472 300 mg (n=92), SNF472 600 mg (n=91), or placebo 
(n=91) by infusion in the hemodialysis lines thrice weekly during hemodialysis 
sessions. The primary end point was change in log coronary artery calcium volume 
score from baseline to week 52. The primary efficacy analysis combined the 
SNF472 treatment groups and included all patients who received at least 1 dose 
of SNF472 or placebo and had an evaluable computed tomography scan after 
randomization.
RESULTS: The mean change in coronary artery calcium volume score was 11% (95% 
CI, 7-15) for the combined SNF472 dose group and 20% (95% CI, 14-26) for the 
placebo group (P=0.016). SNF472 compared with placebo attenuated progression of 
calcium volume score in the aortic valve (14% [95% CI, 5-24] versus 98% [95% CI, 
77-123]; P<0.001) but not in the thoracic aorta (23% [95% CI, 16-30] versus 28% 
[95% CI, 19-38]; P=0.40). Death occurred in 7 patients (4%) who received SNF472 
and 5 patients (6%) who received placebo. At least 1 treatment-emergent adverse 
event occurred in 86%, 92%, and 87% of patients treated with SNF472 300 mg, 
SNF472 600 mg, and placebo, respectively. Most adverse events were mild. Adverse 
events resulted in discontinuation of SNF472 300 mg, SNF472 600 mg, and placebo 
for 14%, 29%, and 20% of patients, respectively.
CONCLUSIONS: Compared with placebo, SNF472 significantly attenuated the 
progression of coronary artery calcium and aortic valve calcification in 
patients with end-stage kidney disease receiving hemodialysis in addition to 
standard care. Future studies are needed to determine the effects of SNF472 on 
cardiovascular events. Registration: URL: https://www.clinicaltrials.gov; Unique 
identifier: NCT02966028.

DOI: 10.1161/CIRCULATIONAHA.119.044195
PMID: 31707860 [Indexed for MEDLINE]
</reference>

<statements>
1. the mean change in coronary artery calcium volume score was "11% (95% CI, 7–15) for the combined SNF472 dose group and 20% (95% CI, 14–26) for the placebo group (P=0.016)."
</statements>

Begin the assessment now. Output only the JSON list, without any conversational text or explanations.